Education
About Us
Working with TipRanks
Follow Us
Rigel Pharmaceuticals (RIGL)
NASDAQ:RIGL
RIGL Stock Chart & Stats
$44.50
-$0.99(-5.79%)
At close: 4:00 PM EST
$44.50
-$0.99(-5.79%)
Day’s Range― - ―
52-Week Range$15.50 - $52.24
Previous CloseN/A
Volume99.93K
Average Volume (3M)527.34K
Market Cap
$807.73M
Enterprise Value$466.43M
Total Cash (Recent Filing)$137.14M
Total Debt (Recent Filing)$60.88M
Price to Earnings (P/E)7.2
Beta1.92
Next Earnings
Mar 03, 2026EPS Estimate
1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.46
Shares Outstanding18,151,344
10 Day Avg. Volume630,663
30 Day Avg. Volume527,339
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)89.93
Price to Sales (P/S)1.65
P/FCF Ratio9.41
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue1.65
Enterprise Value/Gross Profit1.78
Enterprise Value/Ebitda3.75
Forecast
1Y Price Target
$51.50Price Target Upside15.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyClinical data show meaningful responses in a hard-to-treat low-risk MDS population, including sustained transfusion independence and improvements in patient quality of life.
Development Milestones And Upcoming DataEnrollment into the dose expansion phase and planned data presentations at major scientific meetings could increase program visibility and clarify clinical potential.
Pipeline Prioritization And Regulatory StrategyManagement has prioritized the R289 program and plans engagement with regulators to explore a registrational pathway, signaling strategic commitment to advancing the asset.
Bears Say
Clinical Outcome RiskA failed or inconclusive clinical trial outcome could materially undermine the program's prospects and impede stock upside toward analyst targets.
Financing RiskInability to secure adequate funding for further development or commercialization could force resource constraints, delaying programs or diluting shareholder value.
Safety And Tolerability ConcernsObservation of a dose-limiting toxicity at higher dose levels and ongoing adverse events could constrain dosing, slow development, or alter the benefit-risk profile.
Rigel News
RIGL FAQ
What was Rigel Pharmaceuticals’s price range in the past 12 months?
Rigel Pharmaceuticals lowest stock price was $15.50 and its highest was $52.24 in the past 12 months.
What is Rigel Pharmaceuticals’s market cap?
Rigel Pharmaceuticals’s market cap is $807.73M.
When is Rigel Pharmaceuticals’s upcoming earnings report date?
Rigel Pharmaceuticals’s upcoming earnings report date is Mar 03, 2026 which is in 52 days.
How were Rigel Pharmaceuticals’s earnings last quarter?
Rigel Pharmaceuticals released its earnings results on Nov 04, 2025. The company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $0.9 by $0.56.
Is Rigel Pharmaceuticals overvalued?
According to Wall Street analysts Rigel Pharmaceuticals’s price is currently Undervalued.
Does Rigel Pharmaceuticals pay dividends?
Rigel Pharmaceuticals does not currently pay dividends.
What is Rigel Pharmaceuticals’s EPS estimate?
Rigel Pharmaceuticals’s EPS estimate is 1.06.
How many shares outstanding does Rigel Pharmaceuticals have?
Rigel Pharmaceuticals has 18,151,344 shares outstanding.
What happened to Rigel Pharmaceuticals’s price movement after its last earnings report?
Rigel Pharmaceuticals reported an EPS of $1.46 in its last earnings report, beating expectations of $0.9. Following the earnings report the stock price went up 33.369%.
Which hedge fund is a major shareholder of Rigel Pharmaceuticals?
Currently, no hedge funds are holding shares in RIGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rigel Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.50 (15.73% Upside)
$51.50 (15.73% Upside)
Blogger Sentiment
Bullish
RIGL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 9.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 15.9%
Last 30 Days ▲ 15.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
173.84%
12-Months-Change
Fundamentals
Return on Equity
220.06%
Trailing 12-Months
Asset Growth
73.96%
Trailing 12-Months
Company Description
Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
RIGL Company Deck
RIGL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Rigel Pharmaceuticals' strong financial performance, significant increases in revenue and net product sales, and advancements in their drug development pipeline. Despite the termination of a specific CNS program by Eli Lilly, the overall tone was positive, focusing on growth and expansion opportunities.View all RIGL earnings summariesRIGL Stock 12 Month Forecast
Average Price Target
$51.50
▲(15.73% Upside)
Technical Analysis
Ownership Overview
2.57% Insiders
26.67% Mutual Funds
21.12% Other Institutional Investors
34.57% Public Companies and Individual Investors